Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jpc.12202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study.
J Thorac Oncol
January 2025
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Introduction: Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced non-small cell lung cancer (NSCLC) as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reactions (IRR) rate.
Methods: The phase 2 SKIPPirr study (NCT05663866) enrolled patients with EGFR-mutated (Ex19del/L858R) advanced NSCLC after progression on osimertinib and platinum-based chemotherapy who received intravenous amivantamab plus oral lazertinib (amivantamab-lazertinib), a third-generation tyrosine kinase inhibitor.
Reduction of vancomycin-associated acute kidney injury with montelukast.
J Infect Dis
January 2025
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy; Houston, Texas, 77204, United States of America.
Background: Vancomycin ranks amongst the most utilized antimicrobial agents in the treatment of serious β-lactam-resistant Gram-positive infections, but its use has been associated with nephrotoxicity. Reduction of acute kidney injury (AKI) has been reported in pre-clinical models with adjuvant montelukast. The purpose of the study was to ascertain if montelukast was associated with a reduction in the prevalence of vancomycin-associated AKI.
View Article and Find Full Text PDFInhibition of leukotrienes and their potential role in type 1 diabetes pathogenesis: implications for montelukast as a therapeutic agent: a case report.
Front Clin Diabetes Healthc
December 2024
Department of Medicine, NU Hospital Group, Trollhättan and Uddevalla, Sweden.
Introduction: Type 1 diabetes involves immune-mediated destruction of insulin-producing beta cells, with eosinophils potentially playing a significant role. Recent studies suggest that leukotriene inhibition might influence this process. This case report presents a novel observation of montelukast, a leukotriene receptor antagonist, reducing insulin requirements in a patient with Latent Autoimmune Diabetes in Adults (LADA).
View Article and Find Full Text PDFMontelukast potentiates the relaxing effect of nifedipine in the porcine myometrium.
Pol J Vet Sci
September 2024
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-718 Olsztyn, Poland.
This study analysed the influence of montelukast (MON), a cysteinyl leukotriene receptor antagonist, and nifedipine, an L-type voltage-gated Ca2+ channel blocker, on the contractility of the porcine uterine smooth muscle. Myometrial strips were collected from the sexually immature (n=8), cyclic (12-14 days of the oestrous cycle; n=8) and pregnant (27-28 days of pregnancy; n=8) gilts and stimulated with a) MON or nifedipine at concentrations of 10-8-10-4 M and b) increasing concentrations of nifedipine after previous administration of MON at a concentration of 10-4 M. The changes in the tension, amplitude and frequency of contractions were determined with the Hugo Sachs Elektronik equipment for measuring isometric contractions.
View Article and Find Full Text PDFGenotype-Guided Asthma Treatment Reduces Exacerbations in Children: Meta-Analysis of Two RCTs.
Allergy
December 2024
Department of Pulmonary Medicine, AmsterdamUMC, University of Amsterdam, Amsterdam, The Netherlands.
Background: Long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) are commonly used to treat asthma, however, some children lack response to the addition of LABA. This might be partially due to the presence of the Arg16Gly polymorphism, encoded by rs1042713 G>A in the ADRB2 gene. Carrying the A allele (Arg16) at this variant has been associated with an increased risk of exacerbations despite LABA treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!